ST-316

N/A

Report date: 2025/05/21 14:48:55
First In Class

Base Information

Drug NameST-316
Drug Alias NameST-316
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionCatenin beta 1 inhibitorsWnt signalling pathway inhibitors
TargetsCatenin beta 1
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsColonic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSapience Therapeutics Inc
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsColonic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A